German chemical company BASF says that a modification to the manufacturing process it uses to formulate the chemical intermediate N-ethyldiisoproylamine (EDIPA), has increased its purity of the product to 99.5%.
The compound, which is also known as Huenig's base, is used in the pharmaceutical industry as a proton scavenger necessary for the formulation of various active pharmaceutical ingredients, is favored because it will not react with the product being synthesized.
BASF, the world's largest chemicals manufacturer, said that the new process also uses starting materials which are more environmetally benign than those used previously, adding that it is therefore more sustainable than alternative production methods, while creating significantly lower levels of waste material.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze